A case report of Multi System Atrophy (MSA) with cross over features of Progressive Supranuclear Palsy (PSP)

Main Article Content

Judah Rajendran R
Ramesh Kannan
Hannah Ranjee Prasanth

Article Details

R, J. R., Kannan, R., & Prasanth, H. R. (2021). A case report of Multi System Atrophy (MSA) with cross over features of Progressive Supranuclear Palsy (PSP). International Journal of Clinical and Experimental Ophthalmology, 5(2), 019–022. https://doi.org/10.29328/journal.ijceo.1001038
Research Articles

Copyright (c) 2021 Judah Rajendran R, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Respondek G, Levin J, Höglinger GU. Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Curr Opin Neurol. 2018; 31: 448-454. PubMed: https://pubmed.ncbi.nlm.nih.gov/29746401/

Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999 20; 354: 1771-1775. PubMed: https://pubmed.ncbi.nlm.nih.gov/10577638/

Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997; 49: 1284-1288. PubMed: https://pubmed.ncbi.nlm.nih.gov/9371909/

Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964; 10: 333-359. PubMed: https://pubmed.ncbi.nlm.nih.gov/14107684/

Joutsa J, Gardberg M, Röyttä M, Kaasinen V. Diagnostic accuracy of Parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord. 2014; 20: 840-844. PubMed: https://pubmed.ncbi.nlm.nih.gov/24816002/

Cosseddu M, Benussi A, Gazzina S, Manes MA, Dell'Era V, et al. Natural history and predictors of survival in progressive supranuclear palsy. J Neurol Sci. 2017; 382: 105-107. PubMed: https://pubmed.ncbi.nlm.nih.gov/29111000/

Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017; 88: 402-411. PubMed: https://pubmed.ncbi.nlm.nih.gov/28250027/

Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999; 354: 1771–1775. PubMed: https://pubmed.ncbi.nlm.nih.gov/10577638/

Takanashi M, Ohta S, Matsuoka S, Mori H, Mizuno Y. Mixed multiple system atrophy and progressive supranuclear palsy: a clinical and pathological report of one case. Acta Neuropathol (Berl). 2020; 103: 82–87. PubMed: https://pubmed.ncbi.nlm.nih.gov/11837750/

Gearing M, Olson DA, Watts RL, Mirra SS. Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. Neurology 1994; 44: 1015–1024. PubMed: https://pubmed.ncbi.nlm.nih.gov/8208392/

Dickson DW, Lin WL, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 1999; 9: 721–732. PubMed: https://pubmed.ncbi.nlm.nih.gov/10517510/

Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976–1990. Neurology. 1997; 49: 1284–1288. PubMed: https://pubmed.ncbi.nlm.nih.gov/9371909/

Winter Y, Spottke AE, Stamelou M, et al. Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis. 2011; 8: 438-446. PubMed: https://pubmed.ncbi.nlm.nih.gov/21576919/

Glasmacher SA, Leigh PN, Saha RA. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017; 88: 402-411. PubMed: https://pubmed.ncbi.nlm.nih.gov/28250027/

Multiple System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple system atrophy. N Engl J Med. 2013; 369: 233-234. PubMed: https://pubmed.ncbi.nlm.nih.gov/23758206/

Scholz SW, Houlden H, Schulte C, Sharma M, Li A, et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol. 2009; 65: 610-614. PubMed: https://pubmed.ncbi.nlm.nih.gov/19475667/

Sailor A, Schlz SW, Nalls MA, Schulte C, Federoff M, et al. A genome- wide association study in multiple system atrophy. Neurology. 2016; 87: 1591-1598. PubMed: https://pubmed.ncbi.nlm.nih.gov/27629089/

Vilarino-Guell C, Soto-Ortolaza Al, Rajput A, Mash DC, Papapetropoulos S, et al. MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology. 2011; 76: 670-672. PubMed: https://pubmed.ncbi.nlm.nih.gov/21321341/

Labbe C, Heckman MG, Lorenzo-Betancor O, Murray ME, Ogaki K, et al. MAPT haplotype diversity in multiple system atrophy, Parkinsonism Relat Disord. 2016; 30: 40-45. PubMed: https://pubmed.ncbi.nlm.nih.gov/27374978/

Donker Kaat L, Boon AJ, Azmani A, Kamphorst W, Breteler MMB, et al. Familial aggregation of parkinsonism in progessive Supranuclear Palsy. Neurology. 2009; 73: 98-105. PubMed: https://pubmed.ncbi.nlm.nih.gov/19458322/

Heckman MG, Brennan RR, Labbe C, Soto AI, Koga S, et al. Association of MAPT subhaplotypes with Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurol. 2019; 76: 710-717. PubMed: https://pubmed.ncbi.nlm.nih.gov/30882841/

Im SY, Kim YE, Kim YJ. Genetics of Progressive Supranuclear Palsy. J Mov Disord. 2015; 8: 122-129. PubMed: https://pubmed.ncbi.nlm.nih.gov/26413239/